See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

STAT™ Medical Devices

Roger Huckleberry

STAT™ Medical Devices

Todd speaks about Levemir

Todd Hobbs

Todd speaks about Levemir

Nuevas Pequeñas Molécula Drogas Para El Tipo 2  - Ensayos Humanos En Curso

Christoph Westphal, MD, Ph.D - CEO SIRTRIS (GSK)

Nuevas Pequeñas Molécula Drogas Para El Tipo 2  - Ensayos Humanos En Curso

Victoza Archives

Victoza

Updated 7 weeks ago
FDA Backtracks Over GLP-1s' Effects on Pancreas

The U.S. Food and Drug Administration reports that its review of various animal and human studies does not show a link between GLP-1 drugs used to treat type 2 diabetes and pancreatic maladies, including acute pancreatitis and pancreatic cancer.

Comments 0 comments - Mar 4, 2014 - * * * * *

Weekly Type 2 Drug to Be Delivered Via Needle Patch

A recent agreement between Zosano Pharma, Inc. and Novo Nordisk could lead to the introduction of a once-weekly drug for type 2s that is administered via a micro-needle patch system.

Comments 0 comments - Feb 24, 2014 - * * * * *

First-World Type 2 Drug Market to Reach $47 Billion by 2022

A Massachusetts-based research firm concludes that the first-world market for type 2 drugs and treatments will increase from $27 billion in sales in 2012 to $47 billion in 2022.

Comments 0 comments - Oct 18, 2013 - * * * * *

Lilly Says Its New Injectible Outperforms Three Popular Diabetes Drugs

Good news for Eli Lilly & Co., as well as for type 2s who appreciate the addition of new drugs to treat their condition: Lilly says its once-weekly injectible drug, dulaglutide, has outperformed three other widely taken diabetes drugs in three just-concluded Phase III studies.

Comments 0 comments - Nov 20, 2012 - * * * * *

Lilly Says Its New Injectible Outperforms 3 Popular Diabetes Drugs

Good news for Eli Lilly & Co., as well as for type 2s who appreciate the addition of new drugs to treat their condition: Lilly says its once-weekly injectible drug, dulaglutide, has outperformed three other widely taken diabetes drugs in three just-concluded Phase III studies.

Comments 0 comments - Nov 5, 2012 - * * * * *

Paula Deen: Cooking Up a New Life With Diabetes

Paula Deen, a celebrity Southern chef known for her unrestrained love of butter and sugar, is no stranger to the media. She received a flurry of bad press recently when she revealed that she had been diagnosed with type 2 diabetes three years earlier. Shortly thereafter, she became a spokesperson for Novo Nordisk's Victoza. Following these developments, some critics said that she was a poor role model. 

Comments 2 comments - Aug 28, 2012 - * * * * *

Am I Doing the Right Thing?

Readers occasionally ask us for advice about drugs they are taking. When they do, we refer their questions to a medical professional. In the question below, a Florida reader expresses concerns about the interaction of her diabetes drug with the medicines she takes for asthma.

Comments 0 comments - Mar 29, 2012 - * * * * *

FDA Gives Long-Awaited Nod to Amylin’s Bydureon

After several years of delays and setbacks, Amylin Pharmaceuticals has received FDA approval to begin US marketing of BydureonTM. The first once-a-week type 2 therapy to be offered in the US market, Bydureon is expected to be available by February. Amylin says that its wholesale price will be about $4,200 a year.

Comments 2 comments - Feb 3, 2012 - * * * * *

Novo Says Early Use of Victoza Aids Type 2 Control

News from Danish pharmaceutical manufacturer Novo Nordisk reinforces the growing trend toward using a two-drug combination in the early treatment of type 2 diabetes. (See "A Conversation About Janumet and Earlier Combination Therapy Type 2 Diabetes" for more discussion about the phenomenon.)

Comments 2 comments - Dec 15, 2011 - * * * * *

Novo Says Early Use of Victoza Aids Type 2 Control

News from Danish pharmaceutical manufacturer Novo Nordisk reinforces the growing trend toward using a two-drug combination in the early treatment of type 2 diabetes. (See "A Conversation About Janumet and Earlier Combination Therapy for Type 2 Diabetes" for more discussion about this phenomenon.) In a study it released in Lisbon, Portugal, at the recent meeting of the European Association for the Study of Diabetes, Novo said that combining its recently released drug Victoza® (liraglutide) with another drug early in therapy helps recently diagnosed type 2s achieve greater blood glucose control than they can with a single drug.

Comments 0 comments - Oct 2, 2011 - * * * * *

Next Page »  
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.